Comparative Pharmacology
Head-to-head clinical analysis: READI CAT 2 versus READI CAT 2 SMOOTHIE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: READI CAT 2 versus READI CAT 2 SMOOTHIE.
READI-CAT 2 vs READI-CAT 2 SMOOTHIE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide symporter (NIS) substrate; radioactive iodine-131 emits beta particles that cause DNA damage and apoptosis in thyroid follicular cells.
READI-CAT 2 SMOOTHIE is a medical food containing amino acids (e.g., L-arginine, L-citrulline) that serve as substrates for nitric oxide synthesis, enhancing vasodilation and improving endothelial function. It also provides antioxidants to reduce oxidative stress.
No established standard dosing; not a recognized therapeutic agent.
READI-CAT 2 SMOOTHIE is a medical food product, not a drug. There are no standard pharmacological doses. Use as directed by healthcare provider for catabolic states. Typical adult serving: 1-2 bottles (237 mL each) per day orally.
None Documented
None Documented
Terminal half-life: 4.2 hours (range 3.5–5.0 h) after IV administration; prolonged in renal impairment (up to 12 h).
Not applicable; no active pharmaceutical ingredient with measurable half-life.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; remainder via other pathways.
Not applicable; READI-CAT 2 SMOOTHIE is a nutritional supplement product, not a drug. No significant renal, biliary, or fecal elimination of active drug.
Category C
Category C
Diagnostic Contrast Agent
Diagnostic Contrast Agent